Features
Why Choose BONTAC?
Advantages of NMNH
NMNH: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder. 2. Bontac is a very first manufacture in the world to produce the NMNH powder on the level of high purity, stability. 3. Exclusive “Bonpure” seven-step purification technology, high purity（up to 99%) and stability of production of NMNH powder 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMNH powder 5. Provide one-stop product solution customization service
Advantages of NADH
NADH: 1. Bonzyme whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive Bonpure seven-step purification technology, purity up higher than 98 % 3. Special patented process crystal form, higher stability 4. Obtained a number of international certifications to ensure high quality 5. 8 domestic and foreign NADH patents, leading the industry 6. Provide one-stop product solution customization service
Advantages of NAD
NAD: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Stable supplier of 1000+ enterprises around the world 3. Unique “Bonpure” seven-step purification technology, higher product content and higher conversion rate 4. Freeze drying technology to ensure stable product quality 5. Unique crystal technology, higher product solubility 6. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products
Advantages of MNM
NMN: 1. “Bonzyme”Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive“Bonpure”seven-step purification technology, high purity（up to 99.9%) and stability 3. Industrial leading technology: 15 domestic and international NMN patents 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products 5. Multiple in vivo studies show that Bontac NMN is safe and effective 6. Provide one-stop product solution customization service 7. NMN raw material supplier of famous David Sinclair team of Harvard University
We Have The Best Solutions for Your Business
Bontac Bio-Engineering (Shenzhen) Co., Ltd. (hereafter referred to as BONTAC) is a high-tech enterprise established in July 2012. BONTAC integrates R&D, production and sales, with enzyme catalysis technology as the core and coenzyme and natural products as main products. There are six major series of products in BONTAC, involving coenzymes, natural products, sugar substitutes, cosmetics, dietary supplements and medical intermediates.
As the leader of the global NMN industry, BONTAC has the first whole-enzyme catalysis technology in China. Our coenzyme products are widely used in health industry, medical & beauty, green agriculture, biomedicine and other fields. BONTAC adheres to independent innovation, with more than 170 invention patents. Different from the traditional chemical synthesis and fermentation industry, BONTAC has advantages of green low-carbon and high-value-added biosynthesis technology. What’s more, BONTAC has established the first coenzyme engineering technology research center at the provincial level in China which also is the sole in Guangdong Province.
In the future, BONTAC will focus on its advantages of green, low-carbon and high-value-added biosynthesis technology, and build ecological relationship with academia as well as upstream/downstream partners, continuously leading the synthetic biological industry and creating a better life for human beings.
NAD Drip: Materials, NAD Powder, and Effectiveness Explained
NAD Drip therapy, also known as IV NAD therapy, is gaining attention for its potential health benefits. In this comprehensive guide, we delve into the essential components of NAD Drip, including the standards for NAD drip materials, the role of NAD powder in the process, and its effectiveness in promoting overall well-being.
- NAD Drip Materials Standards
- Quality Assurance in Material Selection:
For an effective NAD Drip, ensuring the highest standards in material selection is paramount. IV bags, tubing, and other equipment must meet stringent quality standards to guarantee patient safety and the proper administration of NAD.
- Sterilization and Safety Protocols:
Safety protocols, including sterilization, must be rigorously maintained. The materials involved in the NAD Drip process should adhere to industry best practices for cleanliness and patient safety.
- Professional Administration:
Trained healthcare professionals are essential for administering NAD Drip safely and effectively. Adequate training and certification of personnel are part of the materials standard.
- NAD Powder in NAD Drip
- The Role of NAD Powder:
NAD (Nicotinamide Adenine Dinucleotide) powder is a crucial component of NAD Drip therapy. It is a bioavailable form of NAD that is dissolved in a sterile saline solution for intravenous infusion.
- Purity and Quality:
The quality and purity of NAD powder are vital. The best NAD powder is produced using high-quality raw materials and rigorous manufacturing standards to ensure the absence of impurities or contaminants.
- Dosage and Customization:
NAD Drip therapy can be tailored to individual needs through the precise control of NAD powder dosage. Customized dosages can be formulated based on a patient's specific requirements.
- NAD Drip Effectiveness
- Boosting Cellular Energy:
NAD Drip therapy is believed to enhance cellular energy production by increasing NAD levels in the body. This has potential benefits for overall vitality and performance.
- Anti-Aging Properties:
NAD Drip therapy is also associated with potential anti-aging effects, as NAD plays a key role in DNA repair and cell rejuvenation.
- Support for Wellness:
Many individuals turn to NAD Drip therapy to support general wellness, particularly in conditions related to fatigue, oxidative stress, and age-related health concerns.
NAD Drip therapy is a promising avenue for those seeking to optimize their well-being. Ensuring the highest standards for NAD Drip materials, the quality of NAD powder, and understanding its potential effectiveness is essential for a safe and successful therapy experience.
Featured Products
Collection about BONTAC
User Reviews
What users say about BONTAC
Frequently Asked Question
Do you have any question?
Our updates and blog posts
Application Value of Ginsenoside Rg3 in Targeting BCSCs to Treat Breast Cancer
Introduction Ginsenoside Rg3 is Panaxanediol type tetracyclic triterpenoid saponin monomer extracted from the root of Panax ginseng, which has a wide range of pharmacological effects including anti-tumor, neuroprotection, cardiovascular protection, anti-fatigue, anti-oxidation, hypoglycemia, and enhancement of immune function. This research unveils the potential value of ginsenoside Rg3 in targeting breast cancer stem cells (BCSCs) to treat breast cancer, one of the most common tumor worldwide with significant morbidity and mortality. Ginsenoside Rg3 as anticancer adjuvant Ginsenoside Rg3 can promote the apoptosis of tumor cells, and inhibit tumor growth, infiltration, invasion, metastasis and neovascularization. At the same time, it has the effect of reducing toxicity, increasing efficacy in the joint application with chemotherapeutic drugs, improving immunity of the organism, and reversing multi-drug resistance of tumor cells. Shenyi capsule, a new anticancer drug with ginsenoside Rg3 monomer as the main component, was approved by China FDA and marketed in 2003, which is mainly used in the adjuvant treatment of various tumors. About BCSCs Breast cancer stem cells (BCSCs) are a group of undifferentiated cells with strong ability of self-renewal and differentiation, which is the main reason for poor clinical outcomes and poor efficacy. BCSCs can clonally proliferate under serum-free three-dimensional culture conditions and form mammospheres. BCSCs have specific surface markers (CD44, CD24, CD133, OCT4 and SOX2) or enzymes (ALDH1). BCSCs function as potential drivers of breast cancer, which are resistant to conventional breast cancer clinical treatments such as radiotherapy, leading to breast cancer recurrence and metastasis. The suppressive effect of ginsenoside Rg3 in the progression of breast cancer Ginsenoside Rg3 exerts inhibitory effects on the viability and clonogenicity of breast cancer cells in a time- and dose-dependent manner. In addition, it suppresses mammosphere formation, as evidenced by the spheroid number and diameter. Furthermore, ginsenoside Rg3 reduces the expression of stem cell-related factors (c-Myc, Oct4, Sox2, and Lin28), and decreases the ALDH (+) subpopulation breast cancer cells. Ginsenoside Rg3 as an accelerator of MYC mRNA degradation Ginsenoside Rg3 depresses BCSCs mainly through downregulating the expression of MYC, one of the main cancer stem cell reprogramming factors with a pivotal role in tumor initiation. Its regulatory effect on MYC mRNA stability is chiefly achieved by promoting the microRNA let-7 cluster. Under normal conditions, the let7 family is expressed at low levels in cancer cells, resulting in stable MYC mRNA expression and high c-Myc expression. However, Rg3 treatment leads to the upregulation of let-7 cluster, impairment of MYC mRNA stability, downregulation of c-Myc expression and inhibition of breast cancer stem-like properties. Conclusion The traditional Chinese herbal monomer ginsenoside Rg3 has the potential to suppress breast cancer stem-like properties by destabilizing MYC mRNA at the post-transcriptional level, showing great promise as adjuvant for the treatment of breast cancer. Reference Ning JY, Zhang ZH, Zhang J, Liu YM, Li GC, Wang AM, Li Y, Shan X, Wang JH, Zhang X, Zhao Y. Ginsenoside Rg3 decreases breast cancer stem-like phenotypes through impairing MYC mRNA stability. Am J Cancer Res. 2024 Feb 15;14(2):601-615. PMID: 38455405; PMCID: PMC10915333. BONTAC Ginsenosides BONTAC has been dedicated to the R&D, manufacture and sale of raw materials for coenzyme and natural products since 2012, with self-owned factories, over 170 global patents as well as strong R&D team. BONTAC has rich R&D experience and advanced technology in the biosynthesis of rare ginsenosides Rh2/Rg3, with pure raw materials, higher conversion rate and higher content (up to 99%). One-stop service for customized product solution is available in BONTAC. With unique Bonzyme enzymatic synthesis technology, both S-type and R-type isomers can be accurately synthesized here, with stronger activity and precise targeting action. Our products are subjected to strict third-party self-inspection, which are worth of trustworthy. Disclaimer This article is based on the reference in the academic journal. The relevant information is provided for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be held responsible for any claims, damages, losses, expenses, or costs whatsoever resulting or arising directly or indirectly from your reliance on the information and material on this website.
Further Discussion on the Potential Mechanism of NMN Affecting Neuromuscular Junction
1. Introduction In mammalian cells, the majority of NAD+ is produced from metabolites entering the NAD+ salvage pathway. Nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme of the salvage pathway, which can convert nicotinamide (NAM) into nicotinamide mononucleotide (NMN). Neuronal NAMPT is important for pre-/post-synaptic NMJ function, and maintaining skeletal muscular function and structure. 2. The involvement of NAMPT in NAD+ salvage pathway NAMPT activity has a pivotal role in energy metabolism and homeostasis. NAMPT can condense nicotinamide (NAM) and 5-phosphoribosyl pyrophosphate (PRPP) into nicotinamide mononucleotide (NMN). NMN is subsequently synthesized into NAD+ by nicotinamide mononucleotide adenylyltransferase (NMNAT), the enzyme immediately after NAMPT. 3. The effect of NMN on partially reversing the NMJ impairments in NAMPT-/- cKO mice In the presence of NMN treatment, vesicle endocytosis/exocytosis is improved and endplate morphology is restored in Thy1-NAMPT-/-conditional knockout (cKO) mice. Also, loss of NAMPT in projection neurons impairs the endocytosis and exocytosis of synaptic vesicles at NMJs, but NMN can largely prevent these impairments. Furthermore, NMN treatment restores sarcomere alignment rather than mitochondrial morphology. 4. The underlying mechanism of NMN affecting NMJs The ameliorating effects of NMN on NMJs may be realized via NAMPT-mediated NAD+ salvage pathway, and this speculation is confirmed by the ameliorated synaptic vesicle cycling, endplate morphology, and muscle fiber structure and function post 2-week administration of the NAD+ precursor, NMN. 5. Conclusion Mechanically, the effects of NMN improving NMJ function, endplate morphology and muscular structure and contractility possibly involves NAMPT-mediated NAD+ salvage pathway. NMN holds a great promise as a therapeutic agent for skeletal muscle diseases. Reference Lundt S, Zhang N, Wang X, Polo-Parada L, Ding S. The effect of NAMPT deletion in projection neurons on the function and structure of neuromuscular junction (NMJ) in mice. Sci Rep. 2020;10(1):99. Published 2020 Jan 9. doi:10.1038/s41598-019-57085-4 BONTAC NMN BONTAC is the pioneer of NMN industry and the first manufacturer to launch NMN mass production, with the first whole-enzyme catalysis technology around the world. At present, BONTAC has become the leading enterprise in niche areas of coenzyme products. Notably, BONTAC is the NMN raw material supplier of famous David Sinclair team at the Harvard University, who uses the raw materials of BONTAC in a paper titled “Impairment of an Endothelial NAD+-H2S Signaling Network Is a Reversible Cause of Vascular Aging”. Our services and products have been highly recognized by global partners. Furthermore, BONTAC has the first national and the only provincial independent coenzyme engineering technology research center in Guangdong, China. The coenzyme products of BOMNTAC are widely used in fields such as nutritional health, biomedicine, medical beauty, daily chemicals and green agriculture. Disclaimer This article is based on the reference in the academic journal. The relevant information is provide for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your reliance on the information and material on this website.
Bontac makes it to KPMG's China Biotech Innovation Enterprises Top 50
On April 7th, 2023, KPMG China hosted the second Biotech Innovation 50 Enterprises award ceremony online, with CITIC Securities as a co-organizer. Bontac impressed the panel with its strong R&D capabilities and excellent performance in the synthetic biology sector, earning a spot on the "KPMG China 2023 Biotech Innovation Enterprises Top 50" list. The experts panel spent six months selecting the winners based on five core criteria: technology and product leadership, product pipeline richness and original research ratio, core management and R&D team background, capital market activity, and financial health. Bontac shines with its solid strength The "KPMG China 2023 Biotech Innovation Enterprises Top 50" award evaluated the enterprises from various aspects such as products, technology, team, finance, and funding. The selected enterprises are all high-quality enterprises with outstanding abilities in the biotech field, and being on the list is a great recognition. Bontac Deputy (fourth from the left) Bontac, as a leader in the synthetic biology industry, has always been at the forefront of R&D and production of coenzymes such as NMN, NADH and natural products such as ginsenoside Rh2, stevioside RD, etc. It has a strong comprehensive strength and a promising development potential that won the unanimous approval of the experts panel. From a scientific and technological point of view, Bontac has overcome several technical challenges, obtained more than 160 international patents and over 10 honorary qualifications, and owns more than 600 proprietary enzyme libraries. From the perspective of business scale, Bontac has three production bases that can achieve industrial production of hundreds of tons annually. Bontac also serves customers in more than 20 provinces in China and more than 60 countries. With the accordance of team configuration , Bontac has assembled representatives from four sides: scientists, engineers, entrepreneurs, and investors, empowering the enterprise from multiple dimensions. With the continuous upgrade of health consumption, the gradual release of new policy benefits related to medical regulation, and the rapid development of biopharmaceutical technology industry from a high-tech industry with great potential to a high-tech pillar industry. Biotech enterprises with potential represented by Bontac will leverage policy advantages and ride on market opportunities to integrate diverse resources in the ecosystem, support the development of China's biotech innovation enterprises, and enable win-win cooperation for the entire ecosystem. KPMG Biotech Innovation Enterprises Top 50 KPMG Awarding Ceremony KPMG China launched its first "Biotech Innovation Enterprises Top 50" award in 2021 and received widespread attention and support from the industry. KPMG invited distinguished representatives from research, industry, investment, and enterprise fields to share their insights on the hot topics and trends in biotech and explore the best practices for biotech innovation enterprises. The award also created a resource-matching platform for the selected biotech enterprises with potential, helping them seize the policy direction and capital market opportunities, increase their market visibility, and achieve organic growth from within and outside.